17 completed, 9 recruiting, 8 active not recruiting, 6 terminated. 22 Phase 2, 14 Not applicable, 5 Phase 1, 4 Phase 3, 1 Early Phase 1.
Follow Stage III Breast Cancer: new trials by email Literature Review of Stage III Breast Cancer trials Research Report on Stage III Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Researching the Effect of Exercise on Cancer Exercise - Breast Cancer, Prostate Cancer | Not applicable | Recruiting | City of Hope Medical Center | 51 | 2026-10-30 | 2026-08-27 |
| Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) MINDSET, Enhanced Usual Care (EUC) - Depression, Cancer | Not applicable | Not yet recruiting | Case Comprehensive Cancer Center | 76 | 2026-08-03 | 2026-01-23 |
| [18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer Fluoroestradiol (18F) - Stage III Breast Cancer | Phase 2 | Recruiting | Asan Medical Center | 85 | 2025-12-24 | 2026-01-02 |
| SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response SHR-A1811 - Early Breast Cancer, HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Chuan Wang | 30 | 2025-10-01 | 2025-08-26 |
| A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. Magic Ink - Ductal Carcinoma in Situ, Stage I Breast Cancer | Not applicable | Recruiting | Barbara Ann Karmanos Cancer Institute | 30 | 2025-08-18 | 2025-09-18 |
| A Study of Revaree Plus in People With Breast Cancer Revaree Plus - Breast Cancer, Stage 0 Breast Cancer | Phase 4 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2025-06-20 | 2026-02-06 |
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy Chemoradiation - Invasive Breast Cancer, Stage III Breast Cancer | Phase 3 | Recruiting | Dr. Tabassum Wadasadawala | 858 | 2024-05-14 | 2025-04-13 |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 220 | 2023-12-15 | 2026-10-07 |
| Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment Breast Cancer Female, Stage II Breast Cancer | Recruiting | Gene Solutions | 125 | 2023-09-16 | 2025-09-23 | |
| TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients THRIVE, Health Education Support Program - Breast Cancer, Stage III Breast Cancer | Not applicable | Recruiting | Dana-Farber Cancer Institute | 270 | 2023-03-20 | 2026-07-17 |
| Improving Exercise Capacity With a Tailored Physical Activity Intervention Exercise with Trainerize application, Cardiopulmonary exercise testing, MRI scan - Non Hodgkin Lymphoma, Heart; Functional Disturbance | Not applicable | Active not recruiting | Wake Forest University Health Sciences | 105 | 2023-03-01 | 2026-09-09 |
| Ask Questions (ASQ):Implementation of a Communication Intervention Behavioral Intervention - Stage II Breast Cancer, Stage III Breast Cancer | Not applicable | Completed | Barbara Ann Karmanos Cancer Institute | 81 | 2021-08-25 | 2023-08-16 |
| Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Niraparib, Dostarlimab - Stage I Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 66 | 2021-01-21 | 2026-09-24 |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan - Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 88 | 2020-10-09 | 2025-11-10 |
| MARGetuximab Or Trastuzumab (MARGOT) Paclitaxel, Pertuzumab, Margetuximab - Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 174 | 2020-07-13 | 2025-11-18 |
| A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer docetaxel, epirubicin and cyclophosphamide, docetaxel, epirubicin and cyclophosphamide plus endostar - Stage III Breast Cancer | Phase 2 / Phase 3 | Unknown | Hebei Medical University Fourth Hospital | 300 | 2019-08-01 | 2019-08-09 |
| Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis - Cancer Survivor, Central Obesity | Not applicable | Withdrawn | University of Southern California | 2019-07-29 | 2019-10-24 | |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| Acupuncture Pilot Study for Cancer-related Cognitive Function Acupuncture, Sham Acupuncture, 16 week waiting period + optional Acupuncture - Stage I Breast Cancer, Stage II Breast Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 48 | 2019-07-01 | 2026-08-12 |
Showing 20 of 47. Sign in to see all of them.
Breast Neoplasms (47) · Prostatic Neoplasms (7) · Colorectal Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Uterine Cervical Neoplasms (4) · Carcinoma, Intraductal, Noninfiltrating (3) · Lung Neoplasms (3) · Ovarian Neoplasms (3) · Breast Carcinoma In Situ (2) · Carcinoma, Ductal, Breast (2) · Urinary Bladder Neoplasms (2) · Anus Neoplasms (1) · Appendiceal Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma (1)
Breast Diseases (47) · Neoplasms by Site (47) · Skin Diseases (47) · Skin and Connective Tissue Diseases (47) · Neoplasms (46) · Genital Diseases (8) · Neoplasms by Histologic Type (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Genital Diseases, Male (7) · Genital Neoplasms, Male (7) · Male Urogenital Diseases (7) · Prostatic Diseases (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6)
Cyclophosphamide (5) · Capecitabine (4) · Trastuzumab (4) · Doxorubicin (3) · Paclitaxel (3) · Tamoxifen (3) · Ado-Trastuzumab Emtansine (2) · Anastrozole (2) · Epirubicin (2) · Exercise (2) · Letrozole (2) · PF-05280014 (2) · Vorinostat (2) · exemestane (2) · pertuzumab (2)
Dana-Farber Cancer Institute (7) · Barbara Ann Karmanos Cancer Institute (2) · Jonsson Comprehensive Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Southern California (2) · University of Washington (2) · Wake Forest University Health Sciences (2) · Asan Medical Center (1) · Avelas Biosciences, Inc. (1) · Case Comprehensive Cancer Center (1) · Chuan Wang (1) · City of Hope Medical Center (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Dr. Tabassum Wadasadawala (1)
United States (38) · China (2) · Spain (2) · Belgium (1) · Cyprus (1) · France (1) · Germany (1) · Greece (1) · India (1) · Indonesia (1) · Ireland (1) · Italy (1) · Netherlands (1) · Portugal (1) · South Africa (1)
Adrienne Waks, MD (2) · Amulya C Yellala, MD (1) · Andrea Barsevick, PhD (1) · Anthony Elias, M.D (1) · Chelsea Siwik, PhD (1) · Christina Dieli-Conwright, Ph.D. (1) · Christina Dieli-Conwright, PhD (1) · Emmanouil Saloustros (1) · Eric Winer, MD (1) · Erica L. Mayer, MD, MPH (1) · George Sledge, MD (1) · Haten Soliman, M.D. (1) · Hyehyun Jeong (1) · Ian Krop, MD, PhD (1) · Ingrid Mayer (1)
PMID 24154719, PMID 24464780, PMID 32060053, PMID 32297442, PMID 34092112, PMID 34987618, PMID 35795051, PMID 36892847, PMID 38236702, PMID 38300710, PMID 40097486, PMID 42082270
P30CA014089 (2), N01CN00033 (1), P30CA006973 (1), P30CA012197 (1), P30CA014520 (1), P30CA033572 (1), P30CA036727 (1), P30CA060553 (1), P30CA072720 (1), R01CA214893 (1), R33CA226960 (1), U01CA070095 (1), U01CA271277 (1), U10CA180820 (1), U24CA196172 (1)